Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Lenacapavir, a bi-annual injectable treatment for HIV prevention (PrEP), is being celebrated as a major advancement in the ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir ...

One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...

Who is Nirmala Bandrapalli? Nirmala Bandrapalli was born in Hyderabad and came to the US for higher education over 30 years ...

Initial results published in September by Gilead Sciences for a separate ... Weekly was written and produced by Mend Mariwany. Sound design was by Michelle Macklem, and our theme music is by ...